Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis
Authors
- Xing Zhong (ORCID: https://orcid.org/0000-0001-8819-4687)
- Hao Duan (ORCID: https://orcid.org/0000-0002-7078-8900)
- Yueyue Wang (ORCID: https://orcid.org/0000-0002-2178-3927)
- Xingyu Fan
- Yijun Du (ORCID: https://orcid.org/0000-0002-3434-1407)
- Tianrong Pan (ORCID: https://orcid.org/0009-0004-3918-9362)
- Yue Wang (ORCID: https://orcid.org/0000-0002-3241-6356)
Institutions
- Anhui Medical University (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1186/s40360-025-00898-z
- Citations
- 3
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- National Natural Science Foundation of China